A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

BACKGROUND: Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized trial investigating whether extending adjuvant te...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Balana, Carmen, Vaz, Maria Angeles, Manuel Sepúlveda, Juan, Mesia, Carlos, del Barco, Sonia, Pineda, Estela, Muñoz-Langa, Jose, Estival, Anna, de las Peñas, Ramón, Fuster, Jose, Gironés, Regina, Navarro, Luis Miguel, Gil-Gil, Miguel, Alonso, Miriam, Herrero, Ana, Peralta, Sergio, Olier, Clara, Perez-Segura, Pedro, Covela, Maria, Martinez-García, Maria, Berrocal, Alfonso, Gallego, Oscar, Luque, Raquel, Perez-Martín, Franciso Javier, Esteve, Anna, Munne, Nuria, Domenech, Marta, Villa, Salvador, Sanz, Carolina, Carrato, Cristina
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7746946/
https://ncbi.nlm.nih.gov/pubmed/32328662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa107
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares